Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Medicinal Chemistry

• Publication date

  2008-11-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/092986708786848622PMID 19075650
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bone morphogenetic protein signalling is required for the anti‐mitogenic effect of the proteasome inhibitor MG‐132 on colon cancer cells

  2008cited by this paper
• Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines

  2008cited by this paper
• Inhibition of Histone Deacetylases Promotes Ubiquitin-Dependent Proteasomal Degradation of DNA Methyltransferase 1 in Human Breast Cancer Cells

  2008cited by this paper
• Epidermal Growth Factor Receptor vIII Expression in U87 Glioblastoma Cells Alters Their Proteasome Composition, Function, and Response to Irradiation

  2008cited by this paper
• Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling.

  2008cited by this paper
• Targeting ubiquitin specific proteases for drug discovery.

  2008cited by this paper
• Bortezomib-induced peripheral neurotoxicity: still far from a painless gain

  2007cited by this paper
• Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.

  2007cited by this paper
• Patented small molecule inhibitors in the ubiquitin proteasome system

  2007cited by this paper
• Role of the ubiquitin proteasome system in Alzheimer's disease

  2007cited by this paper
• A Parallel Dose-Escalation Study of Weekly and Twice-Weekly Bortezomib in Combination with Gemcitabine and Cisplatin in the First-Line Treatment of Patients with Advanced Solid Tumors

  2007cited by this paper
• Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.

  2007cited by this paper
• A Phase II Study of Single Agent Bortezomib in Patients with Metastatic Breast Cancer: A Single Institution Experience

  2007cited by this paper
• Novel agents in the treatment of Waldenström's macroglobulinemia.

  2007cited by this paper
• Disease-associated prion protein oligomers inhibit the 26S proteasome.

  2007cited by this paper
• The ubiquitin-proteasome pathway in health and disease of the nervous system.

  2007cited by this paper
• Chaperones and proteases

  2007cited by this paper
• Proteasome inhibitor, bortezomib, for myeloma and lymphoma

  2007cited by this paper
• Neurotoxicity of bortezomib therapy in multiple myeloma: A single‐center experience and review of the literature

  2007cited by this paper
• Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial

  2007cited by this paper
• The proteasome: a worthwhile target for the treatment of solid tumours?

  2007cited by this paper
• Phase I/II Study of Bortezomib Plus Docetaxel in Patients with Advanced Androgen-Independent Prostate Cancer

  2007cited by this paper
• Incorporating Bortezomib into the Treatment of Lung Cancer

  2007cited by this paper
• Quantitative sensory findings in patients with bortezomib-induced pain.

  2007cited by this paper
• Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

  2007cited by this paper
• Localized Treatment with a Novel FDA-Approved Proteasome Inhibitor Blocks the Degradation of Dystrophin and Dystrophin-Associated Proteins in mdx Mice

  2007cited by this paper
• A novel proteasome inhibitor NPI-0052 as an anticancer therapy

  2006cited by this paper
• Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study.

  2006cited by this paper
• Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.

  2006cited by this paper
• Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia

  2006cited by this paper
• Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

  2006cited by this paper
• Life-threatening motor neurotoxicity in association with bortezomib.

  2006cited by this paper
• Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.

  2006cited by this paper
• Failure of protein quality control in amyotrophic lateral sclerosis.

  2006cited by this paper
• Induction of adhesion molecules upon the interaction between eosinophils and bronchial epithelial cells: involvement of p38 MAPK and NF-kappaB.

  2006cited by this paper
• Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.

  2006cited by this paper
• Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation.

  2006cited by this paper
• The battle of the fold: chaperones take on prions.

  2006cited by this paper
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  2006cited by this paper
• Modulation of inflammatory response in sepsis by proteasome inhibition

  2006cited by this paper
• Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer.

  2005cited by this paper
• Bortezomib in combination with dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Proteasome inhibition as a novel therapeutic target in human cancer.

  2005cited by this paper
• A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

  2005cited by this paper
• The Pathobiology of Amyotrophic Lateral Sclerosis: A Proteinopathy?

  2005cited by this paper
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

  2005cited by this paper
• Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

  2005cited by this paper
• Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

  2005cited by this paper
• Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

  2005cited by this paper
• Treatment of relapsed or refractory Waldenström's macroglobulinemia with bortezomib.

  2005cited by this paper
• Impaired proteasome activity and accumulation of ubiquitinated substrates in a hereditary neuropathy model

  2005cited by this paper
• PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.

  2005cited by this paper
• Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

  2005cited by this paper
• A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

  2004cited by this paper
• Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective.

  2004cited by this paper
• Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics

  2004cited by this paper
• Therapeutic potential of exogenous ubiquitin during resuscitation from severe trauma.

  2004cited by this paper
• Mechanism of neurodegenerative disease: role of the ubiquitin proteasome system

  2004cited by this paper
• Ubistatins Inhibit Proteasome-Dependent Degradation by Binding the Ubiquitin Chain

  2004cited by this paper
• Molecular mechanisms of neurotoxicity of pathological prion protein.

  2004cited by this paper
• Effects of exogenous ubiquitin in lethal endotoxemia.

  2004cited by this paper
• Expression of proteasomal proteins in ten different tumor cell lines

  2004cited by this paper
• Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors.

  2004cited by this paper
• Testing the ubiquitin-proteasome hypothesis of neurodegeneration in vivo.

  2004cited by this paper
• Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors

  2004cited by this paper
• Mantle cell lymphoma: established therapeutic options and future directions

  2004cited by this paper
• Molecular shredders: how proteasomes fulfill their role.

  2003cited by this paper
• Characterization of chronic low‐level proteasome inhibition on neural homeostasis

  2003cited by this paper
• Prion proteins meet protein quality control.

  2003cited by this paper
• The proteasome as a target for cancer therapy.

  2003cited by this paper
• The proteasome--an emerging therapeutic target in cancer.

  2003cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Insertion of mutant proteolipid protein results in missorting of myelin proteins

  2003cited by this paper
• Emerging Role for Autophagy in the Removal of Aggresomes in Schwann Cells

  2003cited by this paper
• Autophagy in neurons: a review.

  2002cited by this paper
• The neuropathogenic contributions of lysosomal dysfunction

  2002cited by this paper
• Aggresome formation in neuropathy models based on peripheral myelin protein 22 mutations.

  2002cited by this paper
• Molecular sequelae of proteasome inhibition in human multiple myeloma cells

  2002cited by this paper
• A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.

  2002cited by this paper
• The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction.

  2002cited by this paper
• Proteasome inhibitors: from research tools to drug candidates.

  2001cited by this paper
• Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

  2001cited by this paper
• Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases.

  2001cited by this paper
• Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation.

  2001cited by this paper
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

  2001cited by this paper
• Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB.

  2001cited by this paper
• Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression.

  2000cited by this paper
• Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.

  2000cited by this paper
• Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes.

  2000cited by this paper
• Autophagy, cytoplasm-to-vacuole targeting pathway, and pexophagy in yeast and mammalian cells.

  2000cited by this paper
• The Endosomal-Lysosomal System of Neurons in Alzheimer's Disease Pathogenesis: A Review

  2000cited by this paper
• Ubiquitin‐mediated proteolysis: biological regulation via destruction

  2000cited by this paper
• Experimental models of peripheral neuropathies.

  1999cited by this paper
• The proteasome: a macromolecular assembly designed for controlled proteolysis.

  1999cited by this paper
• The Proteasome, a Novel Protease Regulated by Multiple Mechanisms*

  1999cited by this paper
• PMP22 accumulation in aggresomes: implications for CMT1A pathology.

  1999cited by this paper
• Proteasome inhibitors: a novel class of potent and effective antitumor agents.

  1999cited by this paper
• Aggresomes: A Cellular Response to Misfolded Proteins

  1998cited by this paper
• The ubiquitin system.

  1998cited by this paper

• Design, Synthesis and Biological Evaluation of Coumarin Derivatives as NEDD8 Activating Enzyme Inhibitors in Pancreatic Cancer Cells.

  2021cites this paper
• Clinical manifestations of intravitreal bortezomib injection

  2020cites this paper
• Design, synthesis and biological evaluation of novel naphthoquinone-4-aminobenzensulfonamide/carboxamide derivatives as proteasome inhibitors.

  2020cites this paper
• Minimizing Risk of Cancer Therapeutics.

  2018cites this paper
• Bortezomib induces neuropathic pain through protein kinase C‐mediated activation of presynaptic NMDA receptors in the spinal cord

  2017cites this paper
• GAP-43 slows down cell cycle progression via sequences in its 3'UTR.

  2015cites this paper
• [Chemotherapy-induced Peripheral Neuropathy].

  2015cites this paper
• Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires.

  2014cites this paper
• Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model

  2014cites this paper
• Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system.

  2014cites this paper
• Analysis of Incidence and Risk Factors for Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma

  2014cites this paper
• Steuerung der intrazellulären Proteinmenge durch niedermolekulare Modulatoren des Ubiquitin‐Proteasom‐Systems

  2014cites this paper
• Functionalized mesoporous silica nanoparticles: a possible strategy to target cancer cells reducing peripheral nervous system uptake.

  2013cites this paper
• Correction of Cystathionine β‐Synthase Deficiency in Mice by Treatment with Proteasome Inhibitors

  2013cites this paper
• Algorithmic analysis of drug induced apoptosis and proteasome inhibition in cancer cells based on time-lapse microscopy images

  2013cites this paper
• Eeyarestatin causes cervical cancer cell sensitization to bortezomib treatment by augmenting ER stress and CHOP expression.

  2013cites this paper
• Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.

  2012cites this paper
• Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma

  2012cites this paper
• Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.

  2012cites this paper
• Bortezomib targets the caspase-like proteasome activity in cervical cancer cells, triggering apoptosis that can be enhanced by nelfinavir.

  2011cites this paper
• Proteasome inhibitor up regulates liver antioxidative enzymes in rat model of alcoholic liver disease.

  2011influential citation
• Proteasome inhibition by quercetin triggers macroautophagy and blocks mTOR activity

  2011cites this paper
• The Ubiquitin-Proteasome System and DNA Repair

  2011cites this paper
• Proteasome inhibitor treatment in alcoholic liver disease.

  2011cites this paper
• New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia

  2011cites this paper
• Targeted Therapy in Hematologic Malignancies

  2011cites this paper
• Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies

  2010cites this paper
• Activation of Mutant Enzyme Function In Vivo by Proteasome Inhibitors and Treatments that Induce Hsp70

  2010cites this paper
• The Treatment of Traumatic Brain Injury with Velcade

  2010cites this paper